Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 8.85
- Piotroski Score 5.00
- Grade Buy
- Symbol (ENTX)
- Company Entera Bio Ltd.
- Price $1.78
- Changes Percentage (1.47%)
- Change $0.03
- Day Low $1.75
- Day High $1.80
- Year High $3.35
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/11/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.28
- Trailing P/E Ratio -7.14
- Forward P/E Ratio -7.14
- P/E Growth -7.14
- Net Income $-8,889,000
Income Statement
Quarterly
Annual
Latest News of ENTX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate
Investors are attracted to unprofitable companies like Entera Bio (NASDAQ:ENTX) due to its 139% stock increase in the last year. However, it's crucial to consider the company's cash burn rate and cash...
By Yahoo! Finance | 2 months ago -
Scientex Berhad's (KLSE:SCIENTX) investors will be pleased with their decent 69% return over the last five years
Stock pickers seek stocks to beat the market. For example, Scientex Berhad's stock price has outperformed, but recent gains have slowed. Analyzing fundamentals and EPS growth is crucial for long-term ...
By Yahoo! Finance | 3 months ago
